Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H41NO4 |
Molecular Weight | 467.6401 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]57CC[C@@]2(OC)[C@]([H])(C7)[C@](C)(O)C(C)(C)C)=CC=C3O
InChI
InChIKey=RMRJXGBAOAMLHD-IHFGGWKQSA-N
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
Molecular Formula | C29H41NO4 |
Molecular Weight | 467.6401 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:47 UTC 2023
by
admin
on
Fri Dec 15 15:13:47 UTC 2023
|
Record UNII |
40D3SCR4GZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN07BC51
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
NDF-RT |
N0000175685
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
WHO-ATC |
N07BC01
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
LIVERTOX |
NBK548871
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
NDF-RT |
N0000175689
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
DEA NO. |
9064
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
WHO-ATC |
N02AE01
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
FDA ORPHAN DRUG |
79093
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
SUBOXONE (AUTHORIZED: OPIOID-RELATED DISEASES)
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
WHO-ATC |
N07BC51
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
WHO-VATC |
QN07BC01
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
WHO-VATC |
QN02AE01
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
||
|
FDA ORPHAN DRUG |
541116
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
644073
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
1670
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
CHEMBL511142
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
257-950-6
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
C61656
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
1819
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | RxNorm | ||
|
D002047
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
m2771
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | Merck Index | ||
|
3403
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
BUPRENORPHINE
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
40D3SCR4GZ
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
434
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
Buprenorphine
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
40D3SCR4GZ
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
52485-79-7
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
SUB05985MIG
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
3216
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
DTXSID2022705
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
100000085263
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY | |||
|
DB00921
Created by
admin on Fri Dec 15 15:13:47 UTC 2023 , Edited by admin on Fri Dec 15 15:13:47 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->PARTIAL AGONIST |
PARTIAL AGONIST
BINDING
Ki
|
||
|
TARGET -> AGONIST | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BINDING
Ki
|
||
|
TARGET -> INHIBITOR |
BINDING
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
receptor binding and pharmacological activity
|
||
|
METABOLITE ACTIVE -> PARENT |
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
receptor binding and pharmacological activity
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||